Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fried

Showing results (331-340 of 383) with videos related to

Pageof 39
Sort By:
Journal of Hepatology|September 15, 2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGETStuart C Gordon, Andrew J Muir, Joseph K Lim, et al.
Journal of Viral Hepatitis|January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral TherapyAmit G Singal, K Rajender Reddy, Massimo Colombo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2021
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH StudyMary J Thomson, Marina Serper, Vandana Khungar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 11, 2019
HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype DefinitionWillem P Brouwer, Qian Zhao, Bettina E Hansen, et al.
The New England Journal of Medicine|July 1, 2005
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BGeorge K K Lau, Teerha Piratvisuth, Kang Xian Luo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 22, 2016
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET StudyJordan J Feld, Raoel Maan, Stefan Zeuzem, et al.
Contemporary Clinical Trials|July 15, 2018
The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trialRae Jean Proeschold-Bell, Donna M Evon, Christina Makarushka, et al.
Hepatology (Baltimore, Md.)|February 15, 2001
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis CK R Reddy, T L Wright, P J Pockros, et al.
Contemporary Clinical Trials|March 27, 2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatmentDonna M Evon, Carol E Golin, Paul Stewart, et al.
Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.
Pageof 39

Showing results (331-340 of 383) with videos related to

Sort By:
Pageof 39
Journal of Hepatology|September 15, 2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGETStuart C Gordon, Andrew J Muir, Joseph K Lim, et al.
Journal of Viral Hepatitis|January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral TherapyAmit G Singal, K Rajender Reddy, Massimo Colombo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2021
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH StudyMary J Thomson, Marina Serper, Vandana Khungar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 11, 2019
HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype DefinitionWillem P Brouwer, Qian Zhao, Bettina E Hansen, et al.
The New England Journal of Medicine|July 1, 2005
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BGeorge K K Lau, Teerha Piratvisuth, Kang Xian Luo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 22, 2016
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET StudyJordan J Feld, Raoel Maan, Stefan Zeuzem, et al.
Contemporary Clinical Trials|July 15, 2018
The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trialRae Jean Proeschold-Bell, Donna M Evon, Christina Makarushka, et al.
Hepatology (Baltimore, Md.)|February 15, 2001
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis CK R Reddy, T L Wright, P J Pockros, et al.
Contemporary Clinical Trials|March 27, 2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatmentDonna M Evon, Carol E Golin, Paul Stewart, et al.
Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.
Pageof 39